ALXO Alx Oncology Holdings Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALXO

Price (delayed)

$6.05

Market cap

$315.21M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.71

Enterprise value

$310.87M

ALX Oncology Holdings Inc. operates as a clinical stage immuno-oncology company. The Company focuses on helping patients fight cancer by developing therapies that bridge the innate and adaptive immune system. ...

Highlights
The quick ratio has dropped by 53% year-on-year and by 3.7% since the previous quarter
Alx Oncology Holdings's equity has decreased by 32% YoY and by 13% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://alxoncology.com
Peers: OMGA ONCT

Key stats

What are the main financial stats of ALXO
Market
Shares outstanding
52.1M
Market cap
$315.21M
Enterprise value
$310.87M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.85
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$164.6M
EBITDA
-$163.76M
Free cash flow
-$141.2M
Per share
EPS
-$3.71
Free cash flow per share
-$2.82
Book value per share
$3.27
Revenue per share
$0
TBVPS
$4.24
Balance sheet
Total assets
$212.65M
Total liabilities
$48.46M
Debt
$9.7M
Equity
$164.2M
Working capital
$135.64M
Liquidity
Debt to equity
0.06
Current ratio
5.21
Quick ratio
4.89
Net debt/EBITDA
0.03
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-72.2%
Return on equity
-90.4%
Return on invested capital
-88.4%
Return on capital employed
-91.2%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALXO stock price

How has the Alx Oncology Holdings stock price performed over time
Intraday
-0.82%
1 week
-1.63%
1 month
2.89%
1 year
3.24%
YTD
-59.37%
QTD
0.33%

Financial performance

How have Alx Oncology Holdings's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$175.84M
Net income
-$166.2M
Gross margin
N/A
Net margin
N/A
ALXO's operating income is down by 30% YoY and by 3.3% QoQ
ALXO's net income is down by 29% year-on-year and by 3.4% since the previous quarter

Growth

What is Alx Oncology Holdings's growth rate over time

Valuation

What is Alx Oncology Holdings stock price valuation
P/E
N/A
P/B
1.85
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is down by 17% year-on-year
Alx Oncology Holdings's equity has decreased by 32% YoY and by 13% QoQ
The price to book (P/B) is 26% less than the last 4 quarters average of 2.5

Efficiency

How efficient is Alx Oncology Holdings business performance
ALXO's return on equity has dropped by 94% year-on-year and by 14% since the previous quarter
The return on assets has dropped by 74% year-on-year and by 11% since the previous quarter
ALXO's return on invested capital has dropped by 62% year-on-year and by 7% since the previous quarter

Dividends

What is ALXO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALXO.

Financial health

How did Alx Oncology Holdings financials performed over time
The quick ratio has dropped by 53% year-on-year and by 3.7% since the previous quarter
Alx Oncology Holdings's current ratio has plunged by 51% YoY
The debt is 94% smaller than the equity
Alx Oncology Holdings's debt to equity has soared by 50% YoY and by 20% from the previous quarter
Alx Oncology Holdings's equity has decreased by 32% YoY and by 13% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.